Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway

Zhu, 1993, Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver, J Biol Chem, 268, 26817, 10.1016/S0021-9258(19)74184-2 Park, 2007, Thiazolidinedione class of peroxisome proliferator-activated receptor {gamma} agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats, J Pharmacol Exp Ther, 320, 1002, 10.1124/jpet.106.113472 Bernardo, 2006, Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT 1026, a derivative of flurbiprofen, J Neurochem, 92, 895, 10.1111/j.1471-4159.2004.02932.x Ricote, 1998, Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein, Proc Natl Acad Sci USA, 95, 7614, 10.1073/pnas.95.13.7614 Ji, 2010, PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways, Inflamm Res, 59, 921, 10.1007/s00011-010-0203-7 Has, 2007, Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics, Anticancer drugs, 18, 237, 10.1097/CAD.0b013e328011e67d Lui, 2005, Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR (gamma) fusion oncogene, Oncogene, 24, 1467, 10.1038/sj.onc.1208135 Burgermeister, 2003, Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells, Oncogene, 22, 3888, 10.1038/sj.onc.1206625 Chintharlapalli, 2004, 1,1-Bis(3′-indolyl)-1-(p-subs titutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells, Cancer Res, 64, 5994, 10.1158/0008-5472.CAN-04-0399 Llaverias, 2004, Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism, J Lipid Res, 45, 2015, 10.1194/jlr.M400049-JLR200 Keshamouni, 2004, Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer, Oncogene, 23, 100, 10.1038/sj.onc.1206885 Dong, 2013, Anticancer activities of PPARg in breast cancer are context-dependent, Am J Pathol, 182, 1972, 10.1016/j.ajpath.2013.03.005 Lehrke, 2005, The many faces of PPARγ, Cell, 123, 993, 10.1016/j.cell.2005.11.026 Lowel, 1999, PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function, Cell, 99, 239, 10.1016/S0092-8674(00)81654-2 Charbonnel, 2007, Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials, Fundam Clin Pharmacol, 21, 19, 10.1111/j.1472-8206.2007.00533.x Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial, The Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Blaschke, 2006, Vascular effects of TZDs: new implications, Vasc Pharmacol, 45, 3, 10.1016/j.vph.2005.11.009 Chang, 2000, Induction of differentiation and apoptosis by ligands of PPARγ in non-small cell lung cancer, Cancer Res, 60, 1129 Goetze, 1999, PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells, J Cardiovasc Pharmacol, 33, 798, 10.1097/00005344-199905000-00018 Kubota, 1998, Ligand for PPARγ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo, Cancer Res, 58, 3344 Elstner, 1998, Ligands for PPARγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc Natl Acad Sci USA, 95, 8806, 10.1073/pnas.95.15.8806 Dhillon, 2007, MAP kinase signalling pathways in cancer, Oncogene, 26, 3279, 10.1038/sj.onc.1210421 Adams, 1997, Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site, J Biol Chem, 272, 5128, 10.1074/jbc.272.8.5128 Camp, 1997, Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase, J Biol Chem, 272, 10811, 10.1074/jbc.272.16.10811 Hu, 1996, Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma, Science, 274, 2100, 10.1126/science.274.5295.2100 Aouadi, 2006, Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages, Diabetes, 55, 281, 10.2337/diabetes.55.02.06.db05-0963 Burgermeister, 2008, PPARγ and MEK interactions in cancer, PPAR Res, 2008, 309469, 10.1155/2008/309469 Takeda, 2001, 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells, J Biol Chem, 276, 48950, 10.1074/jbc.M108722200 Traverse, 1992, Sustained activation of the MAPK cascade may be required for differentiation of PC12 cells; Comparison of the effects of nerve growth factor and epidermal growth factor, Biochem J, 288, 351, 10.1042/bj2880351 Wang, 2000, Requirement for ERK activation in cisplatin induced apoptosis, J Biol Chem, 275, 39435, 10.1074/jbc.M004583200 Bornfeldt, 1997, The MAPK pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets, J Clin Invest, 10, 875, 10.1172/JCI119603 Bottazzi, 1999, Regulation of p21 (cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase, J Cell Biol, 146, 1255, 10.1083/jcb.146.6.1255 Liu, 1996, Regulation of p21WAF1/CIP1 expression through MAPK signaling pathway, Cancer Res, 56, 31 Bosch, 1998, Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21 (cip1), J Biol Chem, 273, 22145, 10.1074/jbc.273.34.22145 Pumiglia, 1997, Cell cycle arrest mediated by the MEK/MAPK pathway, Proc Natl Acad Sci USA, 94, 448, 10.1073/pnas.94.2.448 Papageorgiou, 2007, The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines, Expert Opin Ther Targets, 11, 1071, 10.1517/14728222.11.8.1071 Yin, 2001, Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators, Biochem Biophys Res Commun, 286, 916, 10.1006/bbrc.2001.5491 Yu, 2008, Induction of G 1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone: a synthetic peroxisome proliferator-activated receptorγ (PPARγ) ligand, Cell Biol Int, 32, 906, 10.1016/j.cellbi.2008.04.011 Chazotte, 2011, Labeling nuclear DNA with Hoechst 33342, Cold Spring Harb Protoc, 10.1101/pdb.prot5557 Giri, 2009, Curcumin synergizes the growth inhibitory properties of Indian toad (Bufo melanostictus Schneider) skin-derived factor (BM-ANF1) in HCT-116 colon cancer cells, Anticancer Res, 29, 395 Kole, 2011, an isoflavon, showed antiproliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NFκB nuclear translocation, Eur J Pharmacol, 653, 8, 10.1016/j.ejphar.2010.11.026 Koga, 2001, Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines, Hepatology, 33, 1087, 10.1053/jhep.2001.24024 Morrison, 1999, Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis, J Biol Chem, 274, 17088, 10.1074/jbc.274.24.17088 Zhu, 1996, Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator activated receptor gamma, Gene Expr, 6, 185 Keshamouni, 2004, Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in nonsmall-cell lung cancer, Oncogene, 23, 100, 10.1038/sj.onc.1206885 Hu, 2000, Prolonged activation of the MAPK pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line, Cell Growth Differ, 11, 191 Cagnol, 2010, ERK and cell death: mechanisms of ERK induced cell death apoptosis, autophagy and senescence, FEBS J, 277, 2, 10.1111/j.1742-4658.2009.07366.x Tran, 2001, MAPK/ERK overrides the apoptotic signalling from Fas, TNF, and TRAIL receptors, J Biol Chem, 276, 16484, 10.1074/jbc.M010384200 Anderson, 1999, A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside, J Neurosci, 19, 664, 10.1523/JNEUROSCI.19-02-00664.1999 Roovers, 2000, Integrating the MAP kinase signal into the G1 phase cell cycle machinery, Bioessays, 22, 818, 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6 Sturla, 2005, A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death, Cancer Res, 65, 5683, 10.1158/0008-5472.CAN-04-2283 Sebolt-Leopold, 1999, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nat Med, 5, 810, 10.1038/10533 Menapace, 1987, The effects of corticotrophin (ACTH1-24), cyclic AMP and TPA (12-O-tetradecanoyl phorbol-13-acetate) on DNA replication and proliferation of primary rabbit adrenocortical cells in a synthetic medium, Biochem Biophys Res Commun, 148, 1295, 10.1016/S0006-291X(87)80274-7 Herschman, 1989, The tumor promoters 12-Otetradecanoylphorbol-13-acetate and okadaic acid differ in toxicity, mitogenic activity and induction of gene expression, Carcinogenesis, 10, 1495, 10.1093/carcin/10.8.1495 Valette, 1987, Influence of 12-Otetradecanoylphorbol-13-acetate on proliferation and maturation of human breast carcinoma cells (MCF-7): relationship to cell cycle events, Cancer Res, 47, 1615 Younus, 1992, Modulation of mRNA levels during human keratinocyte differentiation, J Cell Physiol, 152, 232, 10.1002/jcp.1041520203 Camp, 1997, Regulation of peroxisome proliferator-activated receptor-gamma activity by mitogen-activated protein kinase, J Biol Chem, 272, 10811, 10.1074/jbc.272.16.10811 Chbicheb, 2011, EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Î″12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells, Biochem Pharmacol, 81, 1087, 10.1016/j.bcp.2011.02.006 Palakurthi, 2001, Anticancer effects of thiazolidinediones are independent of PPARγ and mediated by inhibition of translation initiation, Cancer Res, 61, 6213